BATS:HELX Franklin Genomic Advancements ETF (HELX) Price, Holdings, & News $42.34 -0.77 (-1.79%) As of 10:31 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatings About Franklin Genomic Advancements ETF (BATS:HELX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HELX alerts:Sign Up Key Stats Today's Range$42.34▼$42.3550-Day Range$35.64▼$43.1152-Week Range$29.32▼$43.11Volume1,524 shsAverage Volume1,622 shsMarket Capitalization$16.94 millionAssets Under Management$32.40 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton. Read More Franklin Genomic Advancements ETF ExpensesTypeHELXTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.59%0.53%Other Expenses0.00%0.57%0.53%0.49%0.54%Total Expense0.50%0.72%0.75%0.72%0.73%Fee Waiver0.00%-0.72%-0.67%-0.54%-0.68%Net Expense0.50%0.60%0.63%0.65%0.60% Receive HELX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Franklin Genomic Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HELX ETF News HeadlinesFranklin Templeton ETF Trust - Franklin Genomic Advancements ETFAugust 17, 2026 | money.usnews.comFranklin Genomic Advancements ETF - Markets InsiderJuly 23, 2025 | markets.businessinsider.comSilicon Valley Insider: "Forget AI Stocks"A 25-year Silicon Valley veteran who recommended Nvidia before its 32,000 percent run says the next wave of AI gains wont come from Nvidia, Tesla, or SpaceX. He points to a detail buried on page 37 of the SpaceX IPO filing, tied to Elon Musks plans for 1 million AI satellites, 1 billion humanoid robots, and 200 billion AI chips a year. He says one overlooked sector could benefit most from this spending, and has identified a company trading under $1 that may factor into Musks supply chain.August 24 at 1:00 AM | Brownstone Research (Ad)Franklin Emerging Markets UCITS ETF (FLXE)September 18, 2024 | investing.comFranklin Ethereum ETF (EZET)August 2, 2024 | finance.yahoo.comChainlink Integration Enhances Transparency for 21Shares’ Ether ETFJuly 30, 2024 | msn.comSee More Headlines HELX ETF - Frequently Asked Questions How have HELX shares performed this year? Franklin Genomic Advancements ETF's stock was trading at $36.35 on January 1st, 2026. Since then, HELX stock has increased by 16.5% and is now trading at $42.35. How do I buy shares of Franklin Genomic Advancements ETF? Shares of HELX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Franklin Genomic Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Franklin Genomic Advancements ETF investors own include Merck & Co., Inc. (MRK), iShares iBonds Dec 2025 Term Muni Bond ETF (IBMN), Novavax (NVAX) and AbbVie (ABBV). Fund Details IssuerFranklin Templeton Investments Fund NameFranklin Genomic Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:HELX Inception Date2/25/2020 Fund ManagerMatthew J.Moberg, Joyce Lin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings71 Fund Statistics Assets Under Management$32.40 million Average Daily Volume$0.00 Discount/Premium-0.09% Administrator, Advisor and Custodian AdministratorFranklin Templeton Services, LLC AdvisorFranklin Advisers, Inc. CustodianThe Bank of New York Mellon Corporation DistributorFranklin Templeton Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume2 Put Options2 Call Options0 Miscellaneous Outstanding Shares400,000Beta1.05 Creation Unit50,000 Creation Fee$200.00 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report Top 10 HELX HoldingsGuardant Health (NASDAQ:GH)Holding Weight: 9.38%Natera (NASDAQ:NTRA)Holding Weight: 8.39%Krystal Biotech (NASDAQ:KRYS)Holding Weight: 5.57%Adaptive Biotechnologies (NASDAQ:ADPT)Holding Weight: 4.53%Ligand Pharmaceuticals (NASDAQ:LGND)Holding Weight: 4.24%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.70%Twist Bioscience (NASDAQ:TWST)Holding Weight: 3.54%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.19%Eli Lilly and Company (NYSE:LLY)Holding Weight: 2.96%Travere Therapeutics (NASDAQ:TVTX)Holding Weight: 2.96%Full Holdings DetailsHELX Sector ExposureHELX Industry Exposure This page (BATS:HELX) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
